甘露聚糖肽干预慢性自身免疫性荨麻疹的临床受益评价

Clinical Benefit Evaluation of Mannatide in Intervention with Chronic Autoimmune Urticaria

目的:评价甘露聚糖肽在免疫紊乱性荨麻疹的有效性,探索其在免疫紊乱型荨麻疹免疫调节作用。方法:前瞻性,平行,随机对照试验,将186例自身免疫紊乱荨麻疹分为两组,其中对照组98例采用安慰剂给药(30mg/d),急性期处理应用咪唑斯丁(10mg/d),治疗组口服甘露聚糖肽(30mg/d),其他处理方式与对照组相似。于第四周评价临床疗效及自身抗体水平。结果:甘露聚糖肽组瘙痒评分[(0.9±0.1)vs(2.1±0.5)],风团大小评分[(0.2±0.7)vs(1.0±0.9)],显效率(59.1%vs 34.1%),非常满意率(71.5%vs 26.1%)均优于对照并具有统计学差异(P<0.05或P<0.01)。另外甘露聚糖肽治疗八周后,抗IgE,IgG,抗FcεRIα自身抗体阳性率显著下降,并具有显著的统计学差异(P<0.01)。而对照组无变化。结论:甘露聚糖肽可能通过降低自身抗体提高自身免疫性荨麻疹的临床疗效。

Objective：Evaluate the efficacy mannatide in treatment with autoimmune urticaria,to explore its the immune regulation with autoimmune urticaria.Methods：A parallel randomized controlled clinical study was conducted.The treatment group（n=88） were given mannatide（60mg/d）,and sulfonated austin（10mg/d）was given in acute phase.The control group were just given sulfonated austin（10mg/ d） alone.Results：The pruritus score[（0.2±0.7） vs（1.0±0.9）],wheal score[（0.2±0.7） vs（1.0±0.9）],Significant efficiency（59.1% vs 34.1%）,Very Satisfied rate（71.5% vs 26.1%）were superior to the contol group after 4 weeks therapy.Besides,the positive rate of anti-IgE,IgG,FcεRIα auto-antibody were decrease quickly（P〈0.01）.And there is no difference in the control group.Conclusion：Mannatide can improve the clinical effect through decrease the auto-antibody level.